Gamma-aminobutyric acid type A receptor subunit alpha-1 (GABRA1) (GABRA1)

The GABA-A receptor alpha-1 subunit-containing benzodiazepine site is a specific allosteric binding pocket located at the interface of the alpha-1 and gamma-2 subunits of the heteropentameric GABA-A receptor (Sigel & Steinmann, 2012, PubMed: 22448301). This site is the primary target for benzodiazepines and non-benzodiazepine "Z-drugs" like zolpidem, which act as positive allosteric modulators to enhance the inhibitory effects of the neurotransmitter gamma-aminobutyric acid (GABA) (StatPearls, 2023, NBK470159). Activation of alpha-1-containing receptors primarily mediates sedative, hypnotic, anticonvulsant, and anterograde amnesic effects, distinguishing them from alpha-2 or alpha-3-containing receptors that are more involved in anxiolysis (Rudolph & Knoflach, 2011, PubMed: 21163346). In clinical practice, drugs targeting this site are widely used to treat insomnia and acute seizures (PubChem, 2024). However, chronic modulation can lead to pharmacological tolerance, physical dependence, and a risk of withdrawal syndromes (NIH, 2023). Mutations in the GABRA1 gene are also linked to various forms of epilepsy, highlighting its critical role in maintaining the excitatory-inhibitory balance in the central nervous system (UniProt, 2024, P14867).

Other names

GABA(A) receptor subunit alpha-1BZ1 receptorBenzodiazepine receptor 1Omega-1 receptorGABRA1

Positive allosteric modulation of the GABA-A receptor, which increases the frequency of chloride channel opening in response to GABA binding.